CPL-207280CA is under clinical development by Celon Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CPL-207280CA’s likelihood of approval (LoA) and phase transition for Type 2 Diabetes took place on 04 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CPL-207280CA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CPL-207280CA overview

CPL-207280CA is under development for the treatment of type 2 diabetes and diabetic neuropathy. It is administered through oral route in form of tablet and acts by targeting GPCR (GPR40). It was also under development for the treatment of obesity.

Celon Pharma overview

Celon Pharma a subsidiary of Glatton Sp zoo, is a biopharmaceutical company that researches, develops, produces and distributes generic medicinal products and pharmaceutical preparations to treat cancer, diabetes, neurological and metabolic diseases. The company’s product range includes Aromek, Salmex, Valzek, Lazivir, Donepex and Ketrel. It is investigating drugs against solid tumors, neuropathic pain, asthma, autoimmune diseases, diabetes, psoriasis, Schizophrenia and drug-resistant depression among others. Celon Pharma conducts advanced scientific research and development programs to produce modern drugs. The company works in collaboration with academic and research institutions to discover new therapies. Celon Pharma is headquartered in Lomianki, Mazovia, Poland.

Quick View CPL-207280CA LOA Data

Report Segments
  • Innovator
Drug Name
  • CPL-207280CA
Administration Pathway
  • Oral
Therapeutic Areas
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.